07:00 , Apr 14, 2008 |  BioCentury  |  Finance

Ebb & Flow

PDL BioPharma (NASDAQ:PDLI) last week said it will spin off its biotech pipeline into a newco. It also solidified plans to return more than $500 million, or $4.25 per share, to shareholders in the form...
08:00 , Dec 3, 2007 |  BioCentury  |  Strategy

Buying the Pharm(ion)

Celgene Corp. hopes its acquisition of the 95% of Pharmion Corp. it didn't already own for $2.9 billion in cash and stock will broaden its position in the hematology/oncology space by providing it with rights...
07:00 , Sep 24, 2007 |  BioCentury  |  Finance

Domain exits

Domain exits Company Description Cabrellis [acq'd by Pharmion] Spun out of Conforma when that company was acquired by Biogen Idec; Cabrellis had North American and European rights to amrubicin from Dainippon Sumitomo; the drug is...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Back to School: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

Calsed amrubicin: Phase III start

PHRM plans to start a Phase III trial in early 4Q07. The company submitted an SPA to FDA earlier this year. Last year, PHRM received North American and European rights to the compound when it...
07:00 , May 7, 2007 |  BioCentury  |  Finance

Global visibility

On the face of it, Europe seems to have all the pieces in place. Capital is available from public and private sources, there are clusters of world class science and technology, companies have been able...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

Tragara management update

Tragara Pharmaceuticals Inc. , San Diego, Calif.   Business: Inflammation, Cancer   Hired: Thomas Estok as president and CEO; Christopher LeMasters as CBO; Sara Zaknoen as CMO; and Tracy Lawhon as VP regulatory affairs and...
07:00 , Mar 19, 2007 |  BioCentury  |  Finance

Ebb & Flow

Two new companies, Tragara Pharmaceuticals and Epiphany Biosciences , landed large series A rounds last week. Each was formed around recently in-licensed compounds and hopes to get to a major value inflection point, Phase IIb...
00:44 , Mar 15, 2007 |  BC Extra  |  Top Story

Tragara raises $40 million

Cancer and inflammation company Tragara (San Diego, Calif.) raised $40 million in a series A round. Investors included Domain Associates; ProQuest Investments; Morgenthaler Ventures; Oxford Bioscience Partners; and Mitsubishi International. Tragara's TG01 has completed Phase...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Company News

NovaCardia management update

NovaCardia Inc. , San Diego, Calif.   Business: Cardiovascular   Hired: John Crawford as CFO, formerly CFO of Cabrellis Pharmaceuticals Corp. , now part of Pharmion Corp.  ...